Abstract

Durability and Decay of Treatment Benefit of Cognitive Behavioral Therapy for Irritable Bowel Syndrome: 12-Month Follow-Up

Lackner JM1, Jaccard J2, Radziwon CD3, Firth RS3, Gudleski GD3, Hamilton F4, Katz LA3, Keefer L5, Krasner SS3,6, Ma CX7, Sitrin MD3, Brenner DM8. Am J Gastroenterol. 2018 Nov 14. doi: 10.1038/s41395-018-0396-x. [Epub ahead of print]
 
     

Author information

1 Department of Medicine, Jacobs School of Medicine, Divisions of Behavioral Medicine and Gastroenterology, University at Buffalo, Buffalo, NY, USA. lackner@buffalo.edu.

2 School of Social Work, New York University, New York, NY, USA.

3 Department of Medicine, Jacobs School of Medicine, Divisions of Behavioral Medicine and Gastroenterology, University at Buffalo, Buffalo, NY, USA.

4 Division of Digestive Disease and Nutrition, NIDDK, Bethesda, MD, USA.

5 Department of Medicine, Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

6 Departments of Anesthesiology, Jacobs School of Medicine, University at Buffalo, Buffalo, NY, USA.

7 Department of Biostatistics, University at Buffalo SUNY, Buffalo, NY, USA.

8 Department of Medicine, Feinberg School of Medicine, Division of Gastroenterology, Northwestern University, Chicago, IL, USA.

Abstract

BACKGROUND: There is a need for safe and effective IBS treatments that provide immediate and sustained improvement of IBS symptoms, particularly among more severe patients. The aim was to assess long-term clinical response of cognitive behavioral therapy (CBT) with reference to IBS education.

METHODS: A total of 436 Rome III-diagnosed IBS patients (80% F, M age = 41 years) were randomized to: 4 session home-based CBT (minimal contact (MC-CBT)), 10 session clinic-based CBT (standard (S-CBT)), or 4 session IBS education (EDU). Follow-up occurred at 2 weeks and 3, 6, 9, and 12 months following treatment completion. Treatment response was based a priori on the Clinical Global Improvement Scale (global IBS symptom improvement) and IBS Symptom Severity Scale (IBS-SSS).

RESULTS: Post-treatment CGI gains were generally maintained by MC-CBT patients at quarterly intervals through 12-month follow-up with negligible decay. For MC-CBT and S-CBT, 39 and 33% of respondents maintained treatment response at every follow-up assessment. The corresponding percent for EDU was 19%, which was significantly lower (p < 0.05) than for the CBT groups. On the IBS-SSS, therapeutic gains also showed a pattern of maintenance with trends towards increased efficacy over time in all conditions, with the mean unit reductions between baseline and follows-up being approximately -76 at immediate and approximately -94 at 12 months (-50 = clinically significant).

CONCLUSION: For treatment-refractory IBS patients, home- and clinic-based CBT resulted in substantial and enduring relief of multiple IBS symptoms that generally extended to 12-month post treatment.

© Copyright 2013-2019 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.